Bristol Opts In On Second Neuro Candidate Under Prothena Alliance

 
• By Joseph Haas

Neither the mechanism nor indication is disclosed, but BMS is paying $80m up front for global rights to PRX019, which one analyst speculated might be an Alzheimer’s candidate.

Options
Bristol now has elected options on two of three candidates under Prothena deal • Source: Shutterstock

More from Deals

More from Business